文献速递临床试验与 GCP真实世界研究与卫生经济

早期普瑞巴林减少挥鞭伤后疼痛严重程度的III期三盲随机安慰剂对照试验:PRioRTI试验方案

A Phase III triple-blind randomised placebo-controlled trial to evaluate effectiveness of early treatment with pregabalin to reduce pain severity after whiplash road traffic injury: study protocol for the PRioRTI Trial {1}.
PubMed 文献 · Trials · 2026-02-02

PRioRTI是一项12个月随机、安慰剂对照、三盲III期试验,拟在澳大利亚急诊科招募18-70岁、疼痛≥5/10的急性挥鞭伤相关障碍患者,1:1随机接受普瑞巴林或安慰剂,所有参与者另获循证建议手册。普瑞巴林从75 mg每日两次滴定至300 mg每日两次(4周),随后2周逐渐减量。主要结局为随机化后3个月24小时平均疼痛强度(0-10数字评定量表),并评估残疾、恢复印象、心理困扰、生活质量、不良事件及成本效果。

要点

  • 针对急性挥鞭伤相关障碍且疼痛≥5/10的高危患者,在伤后96小时内启动普瑞巴林。
  • 普瑞巴林从75 mg每日两次滴定至300 mg每日两次,4周滴定后2周减量。
  • 主要结局为随机化后3个月24小时平均疼痛强度(0-10 NRS)。

核心结论

  • PRioRTI试验旨在明确伤后96小时内早期使用普瑞巴林能否降低高危急性挥鞭伤相关障碍患者的疼痛严重程度。

研究设计与样本

  • 12个月随机、安慰剂对照、三盲III期试验,计划从澳大利亚医院急诊科招募18-70岁急性挥鞭伤相关障碍且疼痛≥5/10的患者。
  • 参与者1:1随机接受普瑞巴林或安慰剂,所有参与者另获循证建议手册。

主要发现

  • 本文为试验方案,未报告研究结果。

关键数值与推荐

  • 普瑞巴林起始75 mg每日两次,4周内滴定至300 mg每日两次,随后2周减量。
  • 主要结局为随机化后3个月24小时平均疼痛强度(0-10数字评定量表)。
  • 次要结局包括残疾、患者总体恢复印象、心理困扰、生活质量及不良事件数量。
  • 将进行成本效果分析,并探索治疗效应的潜在中介因素及实施障碍与促进因素。

临床怎么用

  • 若试验成功,结果可能支持对挥鞭伤后高危患者早期使用普瑞巴林以减轻疼痛严重程度。

局限性

  • 本文为研究方案,尚无疗效与安全性结果,结论待试验完成后确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are few effective treatments for acute whiplash-associated disorder (WAD) following a road traffic crash. Early clinical features of central sensitisation, for example widespread hyperalgesia, predict poor recovery. Pregabalin's effects on central sensitisation suggest the potential to prevent or modulate these processes after whiplash injury and prevent later chronic pain. Preliminary evidence indicates that pregabalin provided in the Emergency Department and within 96 hours of injury shows promise to prevent chronic pain. This trial aims to definitively evaluate, in patients at risk for poor recovery following whiplash injury, the effectiveness of early (within 96 hours of injury) pregabalin, compared to placebo, to reduce pain severity. METHODS: The PReventing chronic pain after whiplash Road Traffic Injury (PRioRTI) study is a 12-month randomised, placebo-controlled, triple-blind trial. Individuals with acute WAD (aged 18-70 years) and at risk of poor recovery (pain ≥ 5/10) will be recruited from hospital Emergency Departments in Australia. Participants will be randomly assigned 1:1 to receive pregabalin or placebo. All participants will additionally receive an evidence-based advice booklet. Pregabalin will be commenced at 75 mg bd and titrated to 300 mg bd over 4 weeks, then weaned for 2 weeks. Participants will complete online questionnaires at 6 weeks and 3, 6 and 12 months post-randomisation. The primary outcome will be average pain intensity over 24 hours (0-10 numerical rating scale) at 3 months post-randomisation. Secondary outcomes include disability, patient global impression of recovery, psychological distress, quality of life and the number of adverse events. A cost-effectiveness analysis will be conducted. Potential mediators of treatment effects will be explored. A process evaluation will be conducted to explore barriers and facilitators for future implementation. DISCUSSION: There are few effective treatments for acute WAD. To address this gap, the PRioRTI trial aims to improve health outcomes by targeting central nociceptive processes very soon after whiplash injury using a readily available medication, pregabalin. If successful, the results of this trial will address an urgent unmet need to reduce pain severity after injury and will have clear implications for the early treatment of patients with whiplash injury. TRIAL REGISTRATION {2A AND 2B}: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12624001359527. Registered 13th November 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sterling M, Farrell SF, Ferguson L, et al. A Phase III triple-blind randomised placebo-controlled trial to evaluate effectiveness of early treatment with pregabalin to reduce pain severity after whiplash road traffic injury: study protocol for the PRioRTI Trial {1}. Trials. 2026. PMID: 41629976. doi:10.1186/s13063-026-09479-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。